Consonance Capital Management LP Corcept Therapeutics Inc Transaction History

Consonance Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$10.41 - $14.66 $30 Million - $42.3 Million	-2,882,773 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$9.78 - $12.76 $8.46 Million - $11 Million	-864,680 Reduced 23.07%	2,882,773 $32.1 Million
Q1 2019 May 15, 2019	SELL	$10.03 - $15.71 $24.7 Million - $38.7 Million	-2,464,511 Reduced 39.67%	3,747,453 $44 Million
Q4 2018 Feb 14, 2019	BUY	$11.29 - $17.19 $13.2 Million - $20.2 Million	1,173,090 Added 23.28%	6,211,964 $83 Million
Q3 2018 Nov 14, 2018	BUY	$12.27 - $15.65 $5.04 Million - $6.42 Million	410,457 Added 8.87%	5,038,874 $70.6 Million
Q2 2018 Aug 14, 2018	SELL	$15.3 - $19.69 $8.57 Million - $11 Million	-560,000 Reduced 10.79%	4,628,417 $72.8 Million
Q1 2018 May 15, 2018	SELL	$14.59 - $25.5 $8.62 Million - $15.1 Million	-591,089 Reduced 10.23%	5,188,417 $85.3 Million
Q4 2017 Feb 14, 2018	BUY	$15.77 - $20.72 $29.9 Million - $39.3 Million	1,897,283 Added 48.87%	5,779,506 $104 Million
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $47.8 Million - $74.9 Million	3,882,223	3,882,223 $74.9 Million

337

87.5M

1.08M

852K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.05B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.